Literature DB >> 6735262

Granulosa cell, Sertoli-Leydig cell, and unclassified sex cord-stromal tumors associated with pregnancy: a clinicopathological analysis of thirty-six cases.

R H Young, A G Dudley, R E Scully.   

Abstract

Seventeen granulosa cell, thirteen Sertoli-Leydig cell and six unclassified sex cord-stromal tumors diagnosed during pregnancy or the puerperium were reviewed. Eleven patients presented with abdominal pain or swelling, five in shock, two with virilization, and one with vaginal bleeding. Three asymptomatic patients were explored because of a palpable mass and one because of an adnexal mass found on ultrasound examination. In thirteen patients the tumor was discovered during a cesarean section; five of them had had dystocia and in eight of them the tumor was an incidental finding. All the tumors were Stage I but 13 of them had ruptured; all but one were unilateral. Hemoperitoneum was present in seven cases. On microscopical examination many of the tumors differed from tumors in the same diagnostic categories occurring in the absence of pregnancy by having a disorderly arrangement of their cells, lacking recognizable differentiation in many areas, showing prominent edema, and containing unusually large numbers of lutein or Leydig cells. The last two features were most obtrusive in tumors removed at term. With one exception the patients were initially treated by conservative surgical procedures. Two of them received chemotherapy and two radiation therapy postoperatively. A hysterectomy and salpingo-oophorectomy was performed at a second operation in eight cases; no residual tumor was found in any of the specimens. Only one patient had a recurrence, which was treated surgically. Follow-up for an average of 4.7 years is available for 30 of the 36 patients; all of them were alive and free of disease at the time of the last examination.

Entities:  

Mesh:

Year:  1984        PMID: 6735262     DOI: 10.1016/0090-8258(84)90026-x

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  14 in total

Review 1.  Ovarian tumors with functioning manifestations.

Authors:  Fattaneh A Tavassoli
Journal:  Endocr Pathol       Date:  1994-09       Impact factor: 3.943

2.  Cancer in pregnancy: maternal-fetal conflict.

Authors:  F S Oduncu; R Kimmig; H Hepp; B Emmerich
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-18       Impact factor: 4.553

3.  Endocrine pathology of the ovary : in tribute to Robert E Scully, MD.

Authors:  Esther Oliva; Robert H Young
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

4.  Sertoli-leydig cell tumor of ovary- a diagnostic dilemma.

Authors:  Rohini Dhanya C S; Somanath Padhi; Renu G'boy Varghese
Journal:  J Clin Diagn Res       Date:  2014-03-15

5.  Juvenile granulosa cell ovarian tumor: clinicopathological evaluation of ten patients.

Authors:  Alper Karalök; Tolga Taşçı; Işın Üreyen; Osman Türkmen; Reyhan Öçalan; Gülşah Şahin; Taner Turan; Gökhan Tulunay
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-03-01

6.  Bilateral pregnancy luteoma: a case report.

Authors:  Annu Nanda; Uday A Gokhale; G Rajasekharan Pillai
Journal:  Oman Med J       Date:  2014-09

7.  Cystic Sertoli-Leydig Cell Tumour in a Postmenopausal Woman with Absent Virilising Symptoms: A Diagnostic Challenge.

Authors:  Vidya Monappa; Saritha M Reddy; Ranjini Kudva; Muralidhar V Pai
Journal:  J Clin Diagn Res       Date:  2017-05-01

8.  MR imaging of pregnancy luteoma: a case report and correlation with the clinical features.

Authors:  Hung-Wen Kao; Ching Jiunn Wu; Kuo Teng Chung; Sheng Ru Wang; Cheng Yu Chen
Journal:  Korean J Radiol       Date:  2005 Jan-Mar       Impact factor: 3.500

Review 9.  Hormone-producing tumors of the ovary.

Authors:  Ara Chalvardjian
Journal:  Endocr Pathol       Date:  1990-09       Impact factor: 3.943

Review 10.  Gynecologic cancer in pregnancy.

Authors:  Travis-Riley K Korenaga; Krishnansu S Tewari
Journal:  Gynecol Oncol       Date:  2020-04-05       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.